Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. No metastatic tumor identified


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. At least one macrometastasis
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. Isolated tumor cells or micrometastasis only


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: Which local-invasion category should be recorded for this renal tumor?

Choices:
A. Confined to the kidney
B. Invades perinephric or renal sinus soft tissue
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor


Question: How should regional nodal tumor burden be categorized?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. At least one macrometastasis


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified

Cannot be assessed from the submitted specimen


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only

Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. Isolated tumor cells or micrometastasis only
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. No metastatic tumor identified


Question: What level of nodal metastatic burden is supported by the submitted H&E material?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. At least one macrometastasis
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. Isolated tumor cells or micrometastasis only


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: Which local-invasion category should be recorded for this renal tumor?

Choices:
A. Extends beyond Gerota fascia or directly invades an adjacent organ
B. Confined to the kidney
C. Invades a major renal vein branch or the vena cava
D. Invades perinephric or renal sinus soft tissue

Invades perinephric or renal sinus soft tissue


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Close but negative


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Isolated tumor cells or micrometastasis only
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: How should local extension of this renal tumor be categorized morphologically?

Choices:
A. Extends beyond Gerota fascia or directly invades an adjacent organ
B. Confined to the kidney
C. Invades perinephric or renal sinus soft tissue
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Close but negative

Cannot be assessed from the submitted specimen


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: Which local-invasion category should be recorded for this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Invades a major renal vein branch or the vena cava
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Confined to the kidney


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: What final local-invasion category should be assigned to this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Confined to the kidney
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. No metastatic tumor identified


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified

Cannot be assessed from the submitted specimen


Question: How should regional nodal tumor burden be categorized?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis


Question: What anatomic extent should be entered for this renal tumor in the pathology report?

Choices:
A. Invades a major renal vein branch or the vena cava
B. Confined to the kidney
C. Invades perinephric or renal sinus soft tissue
D. Extends beyond Gerota fascia or directly invades an adjacent organ


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What local anatomic extent is supported for this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Invades a major renal vein branch or the vena cava
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Confined to the kidney


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor


Question: Which level of local invasion is supported by the submitted sections of this renal tumor?

Choices:
A. Extends beyond Gerota fascia or directly invades an adjacent organ
B. Confined to the kidney
C. Invades perinephric or renal sinus soft tissue
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. At least one macrometastasis
B. No metastatic tumor identified
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: What is the greatest anatomic extent of invasion supported for this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Confined to the kidney
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What is the greatest anatomic extent of invasion by this renal tumor?

Choices:
A. Confined to the kidney
B. Invades perinephric or renal sinus soft tissue
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What is the greatest anatomic extent of invasion supported for this renal tumor?

Choices:
A. Confined to the kidney
B. Invades perinephric or renal sinus soft tissue
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: What local anatomic extent is supported for this renal tumor?

Choices:
A. Invades a major renal vein branch or the vena cava
B. Confined to the kidney
C. Invades perinephric or renal sinus soft tissue
D. Extends beyond Gerota fascia or directly invades an adjacent organ

Invades perinephric or renal sinus soft tissue


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Close but negative

Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What level of nodal metastatic burden is supported by the submitted H&E material?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. No metastatic tumor identified


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. At least one macrometastasis


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Close but negative

Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified

Isolated tumor cells or micrometastasis only


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified

Cannot be assessed from the submitted specimen


Question: What is the greatest anatomic extent of invasion by this renal tumor?

Choices:
A. Invades a major renal vein branch or the vena cava
B. Extends beyond Gerota fascia or directly invades an adjacent organ
C. Invades perinephric or renal sinus soft tissue
D. Confined to the kidney

Invades perinephric or renal sinus soft tissue


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. At least one macrometastasis


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only

Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Close but negative


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. Isolated tumor cells or micrometastasis only


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis


Question: Which description best matches the greatest anatomic extent of invasion by this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Invades a major renal vein branch or the vena cava
C. Confined to the kidney
D. Extends beyond Gerota fascia or directly invades an adjacent organ

Invades perinephric or renal sinus soft tissue


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What level of nodal metastatic burden is supported by the submitted H&E material?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: How should local extension of this renal tumor be categorized morphologically?

Choices:
A. Confined to the kidney
B. Invades perinephric or renal sinus soft tissue
C. Invades a major renal vein branch or the vena cava
D. Extends beyond Gerota fascia or directly invades an adjacent organ


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What anatomic extent should be entered for this colorectal tumor in the pathology report?

Choices:
A. Reaches the serosal surface or directly invades an adjacent organ
B. Invades the muscularis propria
C. Limited to the submucosa
D. Extends through muscularis propria into pericolorectal tissue

Extends through muscularis propria into pericolorectal tissue


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: What final local-invasion category should be assigned to this renal tumor?

Choices:
A. Invades a major renal vein branch or the vena cava
B. Extends beyond Gerota fascia or directly invades an adjacent organ
C. Confined to the kidney
D. Invades perinephric or renal sinus soft tissue

Invades perinephric or renal sinus soft tissue


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: Which description best matches the greatest anatomic extent of invasion by this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Confined to the kidney
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What level of nodal metastatic burden is supported by the submitted H&E material?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only

Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: Across the submitted regional lymph nodes, how many contain metastatic tumor on H&E?

Choices:
A. No positive lymph nodes
B. One positive lymph node
C. Four or more positive lymph nodes
D. Two to three positive lymph nodes


Question: What is the total number of H&E-positive regional lymph nodes in this case?

Choices:
A. One positive lymph node
B. No positive lymph nodes
C. Four or more positive lymph nodes
D. Two to three positive lymph nodes


Question: How many examined regional lymph nodes are involved by metastatic tumor?

Choices:
A. One positive lymph node
B. Two to three positive lymph nodes
C. No positive lymph nodes
D. Four or more positive lymph nodes


Question: How many examined regional lymph nodes are involved by metastatic tumor?

Choices:
A. Four or more positive lymph nodes
B. Two to three positive lymph nodes
C. No positive lymph nodes
D. One positive lymph node


Question: What is the total number of H&E-positive regional lymph nodes in this case?

Choices:
A. No positive lymph nodes
B. Four or more positive lymph nodes
C. Two to three positive lymph nodes
D. One positive lymph node


Question: How many examined regional lymph nodes are involved by metastatic tumor?

Choices:
A. No positive lymph nodes
B. One positive lymph node
C. Two to three positive lymph nodes
D. Four or more positive lymph nodes


Question: How many examined regional lymph nodes are involved by metastatic tumor?

Choices:
A. One positive lymph node
B. No positive lymph nodes
C. Two to three positive lymph nodes
D. Four or more positive lymph nodes


Question: How many examined regional lymph nodes are involved by metastatic tumor?

Choices:
A. One positive lymph node
B. No positive lymph nodes
C. Two to three positive lymph nodes
D. Four or more positive lymph nodes


Question: Across the submitted regional lymph nodes, how many contain metastatic tumor on H&E?

Choices:
A. Two to three positive lymph nodes
B. Four or more positive lymph nodes
C. One positive lymph node
D. No positive lymph nodes


Question: What is the total number of H&E-positive regional lymph nodes in this case?

Choices:
A. Four or more positive lymph nodes
B. No positive lymph nodes
C. Two to three positive lymph nodes
D. One positive lymph node


Question: Across the submitted regional lymph nodes, how many contain metastatic tumor on H&E?

Choices:
A. Four or more positive lymph nodes
B. Two to three positive lymph nodes
C. One positive lymph node
D. No positive lymph nodes


Question: How many examined regional lymph nodes are involved by metastatic tumor?

Choices:
A. No positive lymph nodes
B. One positive lymph node
C. Two to three positive lymph nodes
D. Four or more positive lymph nodes


Question: How many examined regional lymph nodes are involved by metastatic tumor?

Choices:
A. Two to three positive lymph nodes
B. No positive lymph nodes
C. One positive lymph node
D. Four or more positive lymph nodes


Question: Across the submitted regional lymph nodes, how many contain metastatic tumor on H&E?

Choices:
A. Two to three positive lymph nodes
B. No positive lymph nodes
C. One positive lymph node
D. Four or more positive lymph nodes


Question: How many examined regional lymph nodes are involved by metastatic tumor?

Choices:
A. Two to three positive lymph nodes
B. One positive lymph node
C. No positive lymph nodes
D. Four or more positive lymph nodes


Question: What is the total number of H&E-positive regional lymph nodes in this case?

Choices:
A. Four or more positive lymph nodes
B. Two to three positive lymph nodes
C. No positive lymph nodes
D. One positive lymph node


Question: Which diagnosis should appear in the final pathology assessment of this endometrial tumor?

Choices:
A. Clear cell carcinoma
B. Serous carcinoma
C. Endometrioid carcinoma
D. Carcinosarcoma


Question: Which diagnosis best represents the morphology of this breast tumor?

Choices:
A. Invasive breast carcinoma of no special type (ductal)
B. Invasive lobular carcinoma
C. Metaplastic carcinoma
D. Mucinous carcinoma

Invasive breast carcinoma of no special type (ductal)


Question: Which diagnosis best represents the morphology of this breast tumor?

Choices:
A. Mucinous carcinoma
B. Invasive breast carcinoma of no special type (ductal)
C. Invasive lobular carcinoma
D. Metaplastic carcinoma

Invasive breast carcinoma of no special type (ductal)


Question: Which histologic diagnosis best fits this breast tumor?

Choices:
A. Mucinous carcinoma
B. Invasive breast carcinoma of no special type (ductal)
C. Metaplastic carcinoma
D. Invasive lobular carcinoma


Question: Which diagnosis is most consistent with the submitted H&E morphology of this urinary bladder neoplasm?

Choices:
A. Urothelial carcinoma with squamous differentiation
B. Sarcomatoid urothelial carcinoma
C. Conventional urothelial carcinoma
D. Micropapillary urothelial carcinoma


Question: Which diagnosis best represents the morphology of this breast tumor?

Choices:
A. Invasive lobular carcinoma
B. Metaplastic carcinoma
C. Invasive breast carcinoma of no special type (ductal)
D. Mucinous carcinoma


Question: Which diagnosis is most consistent with the submitted H&E morphology of this breast neoplasm?

Choices:
A. Metaplastic carcinoma
B. Invasive lobular carcinoma
C. Invasive breast carcinoma of no special type (ductal)
D. Mucinous carcinoma

Invasive breast carcinoma of no special type (ductal)


Question: How should this breast tumor be classified histologically?

Choices:
A. Metaplastic carcinoma
B. Invasive lobular carcinoma
C. Invasive breast carcinoma of no special type (ductal)
D. Mucinous carcinoma

Invasive breast carcinoma of no special type (ductal)


Question: Which diagnosis best accounts for the dominant morphology of this kidney tumor?

Choices:
A. Papillary renal cell carcinoma
B. Chromophobe renal cell carcinoma
C. Renal cell carcinoma, unclassified
D. Clear cell renal cell carcinoma


Question: Which diagnosis should be entered as the histologic type of this urinary bladder tumor?

Choices:
A. Conventional urothelial carcinoma
B. Urothelial carcinoma with squamous differentiation
C. Micropapillary urothelial carcinoma
D. Sarcomatoid urothelial carcinoma


Question: Which histologic diagnosis is supported by the submitted H&E material from this urinary bladder tumor?

Choices:
A. Conventional urothelial carcinoma
B. Micropapillary urothelial carcinoma
C. Urothelial carcinoma with squamous differentiation
D. Sarcomatoid urothelial carcinoma

Urothelial carcinoma with squamous differentiation


Question: What is the most appropriate final histologic diagnosis for this breast tumor?

Choices:
A. Metaplastic carcinoma
B. Invasive breast carcinoma of no special type (ductal)
C. Mucinous carcinoma
D. Invasive lobular carcinoma

Invasive breast carcinoma of no special type (ductal)


Question: Which diagnosis best accounts for the dominant morphology of this endometrial tumor?

Choices:
A. Carcinosarcoma
B. Endometrioid carcinoma
C. Serous carcinoma
D. Clear cell carcinoma


Question: Which diagnosis best represents the morphology of this breast tumor?

Choices:
A. Invasive breast carcinoma of no special type (ductal)
B. Invasive lobular carcinoma
C. Mucinous carcinoma
D. Metaplastic carcinoma


Question: Which diagnosis is most consistent with the submitted H&E morphology of this urinary bladder neoplasm?

Choices:
A. Urothelial carcinoma with squamous differentiation
B. Conventional urothelial carcinoma
C. Sarcomatoid urothelial carcinoma
D. Micropapillary urothelial carcinoma


Question: How should this breast tumor be classified histologically?

Choices:
A. Invasive lobular carcinoma
B. Metaplastic carcinoma
C. Mucinous carcinoma
D. Invasive breast carcinoma of no special type (ductal)

Invasive breast carcinoma of no special type (ductal)


Question: Which diagnosis best accounts for the dominant morphology of this endometrial tumor?

Choices:
A. Serous carcinoma
B. Endometrioid carcinoma
C. Carcinosarcoma
D. Clear cell carcinoma


Question: Which histologic classification is most appropriate for this urinary bladder neoplasm?

Choices:
A. Sarcomatoid urothelial carcinoma
B. Urothelial carcinoma with squamous differentiation
C. Conventional urothelial carcinoma
D. Micropapillary urothelial carcinoma


Question: How should this endometrial tumor be classified histologically?

Choices:
A. Clear cell carcinoma
B. Carcinosarcoma
C. Serous carcinoma
D. Endometrioid carcinoma


Question: Which diagnosis is most consistent with the submitted H&E morphology of this breast neoplasm?

Choices:
A. Invasive breast carcinoma of no special type (ductal)
B. Mucinous carcinoma
C. Invasive lobular carcinoma
D. Metaplastic carcinoma

Invasive breast carcinoma of no special type (ductal)


Question: Using the Nottingham histologic grading system, which grade should be assigned to this tumor?

Choices:
A. Cannot be reliably graded from the submitted H&E slides
B. Grade 1
C. Grade 3
D. Grade 2


Question: How should tumor differentiation appear in the final pathology assessment?

Choices:
A. Poorly differentiated
B. Well differentiated
C. Moderately differentiated
D. Undifferentiated or anaplastic


Question: What is the overall degree of histologic differentiation in this tumor?

Choices:
A. Undifferentiated or anaplastic
B. Moderately differentiated
C. Poorly differentiated
D. Well differentiated


Question: What final grade under the FIGO histologic grading system should be assigned to this tumor?

Choices:
A. Grade 1
B. Grade 2
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 3


Question: What final differentiation category should be assigned to this tumor?

Choices:
A. Undifferentiated or anaplastic
B. Poorly differentiated
C. Moderately differentiated
D. Well differentiated


Question: What grade best represents this tumor under the Nottingham histologic grading system?

Choices:
A. Grade 1
B. Grade 2
C. Grade 3
D. Cannot be reliably graded from the submitted H&E slides


Question: What is the overall degree of histologic differentiation in this tumor?

Choices:
A. Undifferentiated or anaplastic
B. Well differentiated
C. Moderately differentiated
D. Poorly differentiated


Question: What grade under the Nottingham histologic grading system should be entered in the pathology report?

Choices:
A. Grade 1
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 3
D. Grade 2


Question: What is the overall grade of the viable tumor under the FIGO histologic grading system?

Choices:
A. Grade 2
B. Grade 1
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 3


Question: How should this tumor's histologic differentiation be categorized?

Choices:
A. Undifferentiated or anaplastic
B. Poorly differentiated
C. Moderately differentiated
D. Well differentiated


Question: Which grade category under the FIGO histologic grading system best matches this tumor?

Choices:
A. Grade 1
B. Grade 3
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 2


Question: Which category best characterizes this tumor's degree of differentiation?

Choices:
A. Moderately differentiated
B. Well differentiated
C. Poorly differentiated
D. Undifferentiated or anaplastic


Question: What degree of tumor differentiation should be recorded?

Choices:
A. Undifferentiated or anaplastic
B. Moderately differentiated
C. Poorly differentiated
D. Well differentiated


Question: Which grade under the FIGO histologic grading system belongs in the final pathology assessment?

Choices:
A. Grade 3
B. Grade 2
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 1


Question: Which grade under the Nottingham histologic grading system is supported by the tumor morphology?

Choices:
A. Grade 1
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 3
D. Grade 2


Question: What final grade under the FIGO histologic grading system should be assigned to this tumor?

Choices:
A. Grade 3
B. Grade 1
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 2


Question: Which grading assessment is most appropriate under the FIGO histologic grading system?

Choices:
A. Grade 2
B. Grade 3
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 1


Question: Using the Nottingham histologic grading system, which grade should be assigned to this tumor?

Choices:
A. Grade 1
B. Grade 3
C. Grade 2
D. Cannot be reliably graded from the submitted H&E slides


Question: What assessment of tumor necrosis is supported by the submitted tumor material?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: Which status best reflects the evidence for lymphovascular invasion?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: What conclusion regarding vascular invasion is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: What is the appropriate assessment of vascular invasion in this case?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Definitely identified
D. Suspicious but not definitive


Question: What status should be entered for tumor necrosis in the pathology report?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: How should perineural invasion be reported after review of the submitted H&E material?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Not identified after adequate review
D. Cannot be assessed in the submitted material


Question: What conclusion regarding vascular invasion is supported by the available tumor sections?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Definitely identified
D. Not identified after adequate review


Question: Which description best summarizes the status of tumor necrosis in this case?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Not identified after adequate review
D. Definitely identified


Question: How should vascular invasion be reported after review of the submitted H&E material?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: What conclusion regarding tumor necrosis is supported by the available tumor sections?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: What assessment of tumor necrosis is supported by the submitted tumor material?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Suspicious but not definitive


Question: How should tumor necrosis be documented in the final pathology assessment?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Not identified after adequate review


Question: How should lymphovascular invasion be documented in the final pathology assessment?

Choices:
A. Definitely identified
B. Suspicious but not definitive
C. Not identified after adequate review
D. Cannot be assessed in the submitted material


Question: How should vascular invasion be reported after review of the submitted H&E material?

Choices:
A. Definitely identified
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: What is the appropriate assessment of tumor necrosis in this case?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: How should tumor necrosis be reported after review of the submitted H&E material?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Suspicious but not definitive
D. Cannot be assessed in the submitted material


Question: What assessment of vascular invasion is supported by the submitted tumor material?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: Which description best summarizes the status of vascular invasion in this case?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: What assessment of tumor necrosis is supported by the morphologic evidence?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Definitely identified


Question: Which description best summarizes the status of lymphovascular invasion in this case?

Choices:
A. Cannot be assessed in the submitted material
B. Definitely identified
C. Suspicious but not definitive
D. Not identified after adequate review


Question: What assessment of lymphovascular invasion is supported by the morphologic evidence?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: What conclusion regarding lymphovascular invasion is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Suspicious but not definitive
D. Cannot be assessed in the submitted material


Question: How should lymphovascular invasion be documented in the final pathology assessment?

Choices:
A. Suspicious but not definitive
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Definitely identified


Question: What assessment of perineural invasion is supported by the submitted tumor material?

Choices:
A. Cannot be assessed in the submitted material
B. Definitely identified
C. Not identified after adequate review
D. Suspicious but not definitive


Question: What assessment of vascular invasion is supported by the morphologic evidence?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Not identified after adequate review
D. Cannot be assessed in the submitted material


Question: How should vascular invasion be reported after review of the submitted H&E material?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Suspicious but not definitive
D. Definitely identified


Question: How should tumor necrosis be reported after review of the submitted H&E material?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Definitely identified
D. Not identified after adequate review


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative

Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative

Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only

Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. At least one macrometastasis
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. Isolated tumor cells or micrometastasis only


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. Isolated tumor cells or micrometastasis only
D. At least one macrometastasis


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Close but negative

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Close but negative


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative

Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative

Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor


Question: After review of the submitted nodal material, which grouped pathologic N category applies?

Choices:
A. pN2
B. pN1
C. pN0
D. pN3


Question: What grouped pathologic stage is supported after integrating the submitted case material?

Choices:
A. Stage III
B. Stage IV
C. Stage I
D. Stage II


Question: After review of the submitted nodal material, which grouped pathologic N category applies?

Choices:
A. pN3
B. pN0
C. pN2
D. pN1


Question: Which pathologic T group is supported by the complete case review?

Choices:
A. pT1
B. pT2
C. pT4
D. pT3


Question: What grouped pN category best summarizes regional nodal involvement in this case?

Choices:
A. pN3
B. pN2
C. pN0
D. pN1


Question: After review of the submitted nodal material, which grouped pathologic N category applies?

Choices:
A. pN0
B. pN1
C. pN2
D. pN3


Question: After review of all submitted tumor material, which grouped pathologic T category applies?

Choices:
A. pT3
B. pT4
C. pT1
D. pT2


Question: Which pathologic N group is supported after case-level review?

Choices:
A. pN1
B. pN0
C. pN3
D. pN2


Question: Which pathologic T group is supported by the complete case review?

Choices:
A. pT1
B. pT2
C. pT4
D. pT3


Question: After case-level review, which grouped AJCC pathologic stage should be assigned?

Choices:
A. Stage IV
B. Stage II
C. Stage I
D. Stage III


Question: Which pathologic N group is supported after case-level review?

Choices:
A. pN1
B. pN3
C. pN2
D. pN0


Question: What grouped pN category best summarizes regional nodal involvement in this case?

Choices:
A. pN3
B. pN2
C. pN0
D. pN1


Question: After review of all submitted tumor material, which grouped pathologic T category applies?

Choices:
A. pT2
B. pT4
C. pT3
D. pT1


Question: What grouped pN category best summarizes regional nodal involvement in this case?

Choices:
A. pN3
B. pN2
C. pN1
D. pN0


Question: What grouped pathologic stage is supported after integrating the submitted case material?

Choices:
A. Stage III
B. Stage II
C. Stage IV
D. Stage I


Question: Which pathologic N group is supported after case-level review?

Choices:
A. pN1
B. pN2
C. pN3
D. pN0


Question: Which pathologic N group is supported after case-level review?

Choices:
A. pN1
B. pN3
C. pN2
D. pN0


Question: What grouped pN category best summarizes regional nodal involvement in this case?

Choices:
A. pN1
B. pN2
C. pN3
D. pN0


Question: What grouped pN category best summarizes regional nodal involvement in this case?

Choices:
A. pN2
B. pN0
C. pN1
D. pN3


Question: What grouped pN category best summarizes regional nodal involvement in this case?

Choices:
A. pN0
B. pN1
C. pN2
D. pN3


Question: Which overall AJCC pathologic stage group best summarizes this case?

Choices:
A. Stage III
B. Stage I
C. Stage IV
D. Stage II


Question: What grouped pathologic stage is supported after integrating the submitted case material?

Choices:
A. Stage II
B. Stage IV
C. Stage I
D. Stage III


Question: After review of all submitted tumor material, which grouped pathologic T category applies?

Choices:
A. pT2
B. pT3
C. pT1
D. pT4


Question: Which pathologic N group is supported after case-level review?

Choices:
A. pN0
B. pN1
C. pN2
D. pN3


Question: Which overall AJCC pathologic stage group best summarizes this case?

Choices:
A. Stage III
B. Stage I
C. Stage IV
D. Stage II


Question: After review of the submitted nodal material, which grouped pathologic N category applies?

Choices:
A. pN2
B. pN1
C. pN3
D. pN0


Question: Which pathologic N group is supported after case-level review?

Choices:
A. pN0
B. pN3
C. pN1
D. pN2


Question: After review of the submitted nodal material, which grouped pathologic N category applies?

Choices:
A. pN2
B. pN1
C. pN0
D. pN3


Question: After case-level review, which grouped AJCC pathologic stage should be assigned?

Choices:
A. Stage II
B. Stage IV
C. Stage III
D. Stage I


Question: What grouped pT category best summarizes the primary tumor in this case?

Choices:
A. pT4
B. pT1
C. pT2
D. pT3


Question: After case-level review, which grouped AJCC pathologic stage should be assigned?

Choices:
A. Stage IV
B. Stage II
C. Stage I
D. Stage III


Question: After review of the submitted nodal material, which grouped pathologic N category applies?

Choices:
A. pN2
B. pN0
C. pN3
D. pN1


Question: After review of all submitted tumor material, which grouped pathologic T category applies?

Choices:
A. pT4
B. pT2
C. pT3
D. pT1


Question: After review of the submitted nodal material, which grouped pathologic N category applies?

Choices:
A. pN2
B. pN1
C. pN0
D. pN3


Question: What grouped pT category best summarizes the primary tumor in this case?

Choices:
A. pT2
B. pT1
C. pT3
D. pT4


Question: What grouped pN category best summarizes regional nodal involvement in this case?

Choices:
A. pN3
B. pN1
C. pN0
D. pN2


Question: Which finding best summarizes metastatic carcinoma in the submitted regional lymph nodes?

Choices:
A. No metastatic carcinoma is identified in evaluable regional lymph-node tissue
B. The nodal finding is suspicious but not definitive
C. Metastatic carcinoma is identified in at least one regional lymph node
D. Regional lymph-node metastasis cannot be assessed because no evaluable lymph-node tissue is available

Metastatic carcinoma is identified in at least one regional lymph node


Question: What is the case-level histologic diagnosis of this primary lung tumor?

Choices:
A. Lung squamous cell carcinoma
B. Large-cell neuroendocrine carcinoma
C. Small-cell lung carcinoma
D. Lung adenocarcinoma


Question: What worst-case margin status should be recorded across all inked margins in this thigh excision?

Choices:
A. All relevant margins are evaluable and negative with clear separation
B. No positive or close margin is established, but at least one relevant margin cannot be assessed
C. At least one relevant inked margin is involved by tumor
D. No margin is involved, but at least one relevant margin is close

At least one relevant inked margin is involved by tumor


Question: What worst-case margin status should be recorded across the ileal and uterine resection specimens?

Choices:
A. No positive or close margin is established, but at least one relevant margin cannot be assessed
B. All relevant margins are evaluable and negative with clear separation
C. At least one relevant inked margin is involved by tumor
D. No margin is involved, but at least one relevant margin is close

No positive or close margin is established, but at least one relevant margin cannot be assessed


Question: How should the case-level differentiation pattern of this lung adenocarcinoma be recorded?

Choices:
A. Predominantly poorly differentiated
B. Predominantly well differentiated
C. Predominantly moderately differentiated
D. Mixed moderately and poorly differentiated

Mixed moderately and poorly differentiated


Question: What is the case-level histologic composition of this endometrial carcinoma?

Choices:
A. Serous carcinoma
B. Endometrioid carcinoma
C. Mixed endometrioid and serous carcinoma
D. Clear cell carcinoma


Question: What is the case-level histologic composition of this breast carcinoma?

Choices:
A. Mixed invasive ductal and lobular carcinoma
B. Mucinous carcinoma
C. Invasive breast carcinoma of no special type (ductal)
D. Invasive lobular carcinoma

Mixed invasive ductal and lobular carcinoma


Question:
During review of a lung case, compare the three submitted H&E WSI sets. Which set can support an answer to the target question, or is the target tissue absent from all three?

Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Candidate WSI Set 3 contains the target-relevant H&E tissue
B. Candidate WSI Set 1 contains the target-relevant H&E tissue
C. Candidate WSI Set 2 contains the target-relevant H&E tissue
D. None of the candidate WSI sets contains target-relevant H&E tissue

Candidate WSI Set 1 contains the target-relevant H&E tissue